| [1] |
胡鑫洋, 高静韬. 世界卫生组织《2024年全球结核病报告》解读. 结核与肺部疾病杂志, 2024, 5(6): 500-504. doi:10.19983/j.issn.2096-8493.2024164.
|
| [2] |
World Health Organization.Global tuberculosis report 2024. Geneva: World Health Organization, 2024.
|
| [3] |
Lanoix JP, Gaudry S, Flicoteaux R, et al. Tuberculosis in the intensive care unit: a descriptive analysis in a low-burden country. Int J Tuberc Lung Dis, 2014, 18(5): 581-587. doi:10.5588/ijtld.13.0901.
pmid: 24903796
|
| [4] |
Hui YM, Pillinger T, Luqmani A, et al. Haemophagocytic lymphohistiocytosis associated with Mycobacterium tuberculosis infection. BMJ Case Rep, 2015, 2015: bcr2014208220. doi:10.1136/bcr-2014-208220.
|
| [5] |
Henter JI. Hemophagocytic Lymphohistiocytosis. N Engl J Med, 2025, 392(6): 584-598. doi:10.1056/NEJMra2314005.
|
| [6] |
Brastianos PK, Swanson JW, Torbenson M, et al. Tuberculosis-associated haemophagocytic syndrome. Lancet Infect Dis, 2006, 6(7): 447-454. doi:10.1016/S1473-3099(06)70524-2.
pmid: 16790385
|
| [7] |
Lerolle N, Laanani M, Galicier L, et al. Factors associated with tuberculosis-associated haemophagocytic syndrome: a multicentre case-control study. Int J Tuberc Lung Dis, 2020, 24(1): 124-130. doi:10.5588/ijtld.19.0856.
pmid: 32005316
|
| [8] |
噬血细胞综合征中国专家联盟, 中华医学会儿科学分会血液学组. 噬血细胞综合征诊治中国专家共识. 中华医学杂志, 2018, 98(2): 91-95. doi:10.3760/cma.j.issn.0376-2491.2018.02.004.
|
| [9] |
Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer, 2007, 48(2): 124-131. doi:10.1002/pbc.21039.
|
| [10] |
中华人民共和国国家卫生和计划生育委员会. WS 288—2017肺结核诊断. 结核与肺部疾病杂志, 2024, 5(4): 376-378. doi:10.19983/j.issn.2096-8493.2024022.
|
| [11] |
中国人民解放军总医院第八医学中心结核病医学部, 《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会. 浅表淋巴结结核的诊断与治疗专家共识. 中国防痨杂志, 2023, 45(6): 531-542. doi:10.19982/j.issn.1000-6621.20230120.
|
| [12] |
中华医学会结核病学分会结核性脑膜炎专业委员会. 2019中国中枢神经系统结核病诊疗指南. 中华传染病杂志, 2020, 38(7): 400-408. doi:10.3760/cma.j.cn311365-20200606-00645.
|
| [13] |
World Health Organization. WHO consolidated guidelines on tuberculosis: Module 4: Treatment-Drug-susceptible tuberculosis treatment. Geneva: World Health Organization, 2022.
|
| [14] |
World Health Organization. WHO consolidated guidelines on tuberculosis: Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization, 2022.
|
| [15] |
Padhi S, Ravichandran K, Sahoo J, et al. Hemophagocytic lymphohistiocytosis: An unusual complication in disseminated Mycobacterium tuberculosis. Lung India, 2015, 32(6): 593-601. doi:10.4103/0970-2113.168100.
|
| [16] |
Canet E, Dantal J, Blancho G, et al. Tuberculosis following kidney transplantation: clinical features and outcome. A French multicentre experience in the last 20 years. Nephrol Dial Transplant, 2011, 26(11): 3773-3778. doi:10.1093/ndt/gfr156.
|
| [17] |
Zhang Y, Liang G, Qin H, et al. Tuberculosis-associated hemophagocytic lymphohistiocytosis with initial presentation of fever of unknown origin in a general hospital: An analysis of 8 clinical cases. Medicine (Baltimore), 2017, 96(16): e6575. doi:10.1097/MD.0000000000006575.
|
| [18] |
Kessler M, Reinig E. HLH Associated with Disseminated Tuberculosis. N Engl J Med, 2020, 382(18): 1749. doi:10.1056/NEJMicm1910558.
|
| [19] |
Zhou S, Zhang D, Li D, et al. Pathogenic mycobacterium upregulates cholesterol 25-hydroxylase to promote granuloma development via foam cell formation. iScience, 2024, 27(3): 109204. doi:10.1016/j.isci.2024.109204.
|
| [20] |
Sturm A, Sun P, Avila-Pacheco J, et al. Genetic factors affecting storage and utilization of lipids during dormancy in Mycobacterium tuberculosis. mBio, 2024, 15(2): e0320823. doi:10.1128/mbio.03208-23.
|
| [21] |
Parikh SA, Kapoor P, Letendre L, et al. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc, 2014, 89(4): 484-492. doi:10.1016/j.mayocp.2013.12.012.
pmid: 24581757
|
| [22] |
Lachmann G, Knaak C, von Haefen C, et al. Diagnostic biomarkers for adult haemophagocytic lymphohistiocytosis in critically ill patients (HEMICU): a prospective observational study protocol. BMJ Open, 2019, 9(10): e032695. doi:10.1136/bmjopen-2019-032695.
|
| [23] |
George MR. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med, 2014, 5: 69-86. doi:10.2147/JBM.S46255.eCollection 2014.
pmid: 24966707
|
| [24] |
Arca M, Fardet L, Galicier L, et al. Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide. Br J Haematol, 2015, 168(1): 63-68. doi:10.1111/bjh.13102.
|